Empiric Antibiotic Treatment for Community-Acquired Pneumonia
For hospitalized adults with moderate-severity community-acquired pneumonia, initiate ceftriaxone 1–2 g IV once daily plus azithromycin 500 mg daily immediately upon diagnosis; this combination provides comprehensive coverage of typical bacterial pathogens and atypical organisms with strong evidence supporting mortality reduction. 1
Outpatient Management
Previously Healthy Adults (No Comorbidities)
Amoxicillin 1 g orally three times daily for 5–7 days is the preferred first-line agent, retaining activity against 90–95% of Streptococcus pneumoniae isolates including many penicillin-resistant strains, with superior pneumococcal coverage compared to oral cephalosporins. 1, 2
Doxycycline 100 mg orally twice daily for 5–7 days serves as an acceptable alternative, offering coverage of both typical bacteria (S. pneumoniae, H. influenzae, M. catarrhalis) and atypical organisms (Mycoplasma, Chlamydophila, Legionella). 1, 2
Macrolide monotherapy (azithromycin 500 mg day 1, then 250 mg daily; or clarithromycin 500 mg twice daily) should only be used when local pneumococcal macrolide resistance is documented <25%; in most U.S. regions resistance is 20–30%, making macrolide monotherapy unsafe as first-line therapy. 1, 2, 3
Adults with Comorbidities or Recent Antibiotic Use
Combination therapy is required: a β-lactam (amoxicillin-clavulanate 875/125 mg twice daily, cefpodoxime, or cefuroxime) plus a macrolide (azithromycin or clarithromycin) or doxycycline 100 mg twice daily. 1, 2
Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) is reserved for patients with β-lactam allergy or when combination therapy is contraindicated, acknowledging FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection). 1, 4, 3
Comorbidities requiring broader coverage include COPD, diabetes, chronic heart/liver/renal disease, malignancy, asplenia, immunosuppression, or antibiotic use within the past 90 days. 1, 2
Inpatient Management (Non-ICU)
Standard Empiric Regimen
Ceftriaxone 1–2 g IV once daily plus azithromycin 500 mg IV or orally daily provides comprehensive coverage for typical pathogens (S. pneumoniae including penicillin-resistant strains with MIC ≤2 mg/L, H. influenzae, M. catarrhalis) and atypical organisms (Mycoplasma, Chlamydophila, Legionella). Strong recommendation, high-quality (Level I) evidence. 1, 2, 3
Alternative β-lactams include cefotaxime 1–2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours, always combined with a macrolide. 1, 3
Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) is equally effective and reserved for penicillin-allergic patients. 1, 4, 3
Critical Timing
Administer the first antibiotic dose in the emergency department immediately upon diagnosis; delays beyond 8 hours increase 30-day mortality by 20–30% in hospitalized patients. 1, 2
Obtain blood cultures and sputum Gram stain/culture before initiating antibiotics in all hospitalized patients to enable pathogen-directed therapy and safe de-escalation. 1, 2
Transition to Oral Therapy
Switch from IV to oral antibiotics when the patient is hemodynamically stable (systolic BP ≥90 mmHg, heart rate ≤100 bpm), clinically improving, afebrile for 48–72 hours, respiratory rate ≤24 breaths/min, oxygen saturation ≥90% on room air, and able to take oral medication—typically by hospital day 2–3. 1, 2
Oral step-down options include amoxicillin 1 g three times daily plus azithromycin 500 mg daily (or azithromycin alone after 2–3 days of IV therapy). 1, 2
Severe CAP Requiring ICU Admission
Mandatory Combination Therapy
Ceftriaxone 2 g IV once daily (or cefotaxime 1–2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours) plus azithromycin 500 mg IV daily is required for all ICU patients; β-lactam monotherapy is linked to significantly higher mortality in critically ill patients with bacteremic pneumococcal pneumonia. Strong recommendation, Level I evidence. 1, 2
Alternative: β-lactam plus a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily). 1, 2
Penicillin-Allergic ICU Patients
- Aztreonam 2 g IV every 8 hours plus a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) provides dual coverage against pneumococcal and gram-negative pathogens. 1, 4
Special Pathogen Coverage (Risk Factor-Based)
Pseudomonas aeruginosa
Add antipseudomonal therapy only when specific risk factors are present: structural lung disease (bronchiectasis, cystic fibrosis), recent hospitalization with IV antibiotics within 90 days, or prior respiratory isolation of P. aeruginosa. 1, 2
Regimen: antipseudomonal β-lactam (piperacillin-tazobactam 4.5 g IV every 6 hours, cefepime 2 g IV every 8 hours, or meropenem 1 g IV every 8 hours) plus ciprofloxacin 400 mg IV every 8 hours or levofloxacin 750 mg IV daily plus an aminoglycoside (gentamicin or tobramycin 5–7 mg/kg IV daily) for dual antipseudomonal coverage. 1, 2
Methicillin-Resistant Staphylococcus aureus (MRSA)
Add MRSA coverage only when risk factors are present: prior MRSA infection/colonization, recent hospitalization with IV antibiotics, post-influenza pneumonia, or cavitary infiltrates on imaging. 1, 2, 4
Regimen: vancomycin 15 mg/kg IV every 8–12 hours (target trough 15–20 µg/mL) or linezolid 600 mg IV every 12 hours, added to the base CAP regimen. 1, 4
Duration of Therapy
Minimum treatment duration is 5 days, continuing until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability. 1, 2, 5, 6
Typical duration for uncomplicated CAP is 5–7 days. 1, 2, 5, 6
Extended courses of 14–21 days are required only for infections caused by Legionella pneumophila, Staphylococcus aureus, or gram-negative enteric bacilli. 1, 2
Recent evidence supports 3-day treatment for non-severe or moderate CAP stabilized at day 3, with 5 days when stability is achieved by day 5. 5, 6
β-Lactam Allergy Alternatives
Outpatient Setting
Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) is the preferred alternative for penicillin-allergic patients. 4
Doxycycline 100 mg twice daily (consider 200 mg first dose) is an acceptable alternative, particularly for patients who cannot tolerate fluoroquinolones. 4, 7
Macrolides (azithromycin or clarithromycin) are alternative options, particularly when treating atypical pathogens, but only in areas where pneumococcal macrolide resistance is <25%. 4
Inpatient Setting
Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) is the preferred treatment for penicillin-allergic hospitalized patients. 4
For severe pneumonia requiring ICU admission in penicillin-allergic patients, use respiratory fluoroquinolone plus aztreonam 2 g IV every 8 hours. 4
Critical Pitfalls to Avoid
Never use macrolide monotherapy in hospitalized patients; it fails to cover typical pathogens such as S. pneumoniae and is associated with treatment failure. 1, 2, 8, 9
Avoid indiscriminate fluoroquinolone use in uncomplicated outpatient CAP due to FDA warnings about serious adverse events and rising resistance; reserve for patients with comorbidities or β-lactam allergy. 1, 2
Do not add broad-spectrum antipseudomonal or MRSA agents routinely; restrict to patients with documented risk factors to prevent unnecessary resistance, adverse effects, and cost. 1, 2
Do not delay antibiotic administration while awaiting culture results; specimens should be collected rapidly, but therapy must start immediately. 1, 2
Avoid extending therapy beyond 7–8 days in responding patients without specific indications, as longer courses increase antimicrobial resistance risk without improving outcomes. 1, 2, 5
Oral cephalosporins (cefuroxime, cefpodoxime) are not first-line agents due to inferior in-vitro activity against S. pneumoniae, lack of atypical coverage, and no demonstrated clinical superiority. 1, 2, 10
Monitoring and Follow-Up
Clinical review at 48 hours (or sooner if symptoms worsen) to assess symptom resolution, oral intake, and treatment response. 1, 2
If no clinical improvement by day 2–3, obtain repeat chest radiograph, inflammatory markers (CRP, white blood cell count), and additional microbiologic specimens to evaluate for complications such as pleural effusion, empyema, or resistant organisms. 1, 2
Routine follow-up at 6 weeks for all patients; chest radiograph only for those with persistent symptoms, abnormal physical findings, or high risk for underlying malignancy (e.g., smokers >50 years). 1, 2
In hospitalized patients, monitor vital signs (temperature, respiratory rate, pulse, blood pressure, oxygen saturation) at least twice daily to detect early deterioration. 1, 2